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binding afﬁnity (Kd¼ 2.3 x 10-7 M). T-cells were transduced
to express the A2-RMF CAR using MSCV retroviral vector.
However, CAR transduced T-cells bearing the low afﬁnity A2-
RMF ScFv did not demonstrate any binding to the A2-RMF
tetramers, and did not demonstrate any in-vitro cytotoxic
activity against A2+/WT-1+ tumor cell targets. We subse-
quently developed an afﬁnity matured ScFv (Kd¼ 3.08 x 10-9
M) to determine if ScFv binding afﬁnity correlated with
functional activity. T-cells transduced to express CARs
bearing the afﬁnity matured A2-RMF ScFv demonstrated
strong binding to the A2-RMF tetramer in all transduced
cells. The afﬁnity matured A2-RMF CAR modiﬁed T-cells
were able to kill A2+/WT-1+ solid tumor or B cell leukemia
cell lines (29% -40% speciﬁc lysis) at E:T ratios of 50:1 and
20:1, in comparison to 1-4% speciﬁc lysis for HLA A2-/WT-1+
or A2+/WT-1- control tumor cell lines. These data demon-
strate that a TCR-mimic CAR bearing scFv against an A2-RMF
complex, can bind to A2-RMF tetramers and effectively lyse
tumor cell targets co-expressing HLA A2 and WT1 in an HLA
restricted and antigen speciﬁc manner. The results also
suggest that the binding afﬁnity of the antibody is important
for effective functional activity of CAR modiﬁed T-cells
directed against epitopes of self tumor associated antigens.182
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Background: Development of novel (immune) therapies is
of utmost importance to improve survival in relapsed pedi-
atric-AML (acute myeloid leukemia). We aim to develop a
powerful and safe therapy consisting of two potentially
synergistic components: Cord Blood (CB) HSCT and vacci-
nation with CB-derived Wilms Tumor-1 (WT1) mRNA-elec-
troporated dendritic cells (DCs).
Materials & Methods: After isolation, the CD34+ CB stem
cells were cultured using a two-step protocol. First, they
were expanded using a combination of (growth) factors
(Flt3L, SCF, IL-3 and IL-6). Next, the cells were differentiated
towards DCs for one week using medium containing Flt3L,
SCF, GM-CSF, IL-4 and human serum followed by a CYTOMIX
(IL-1beta, IL-6, TNF-alpha and PGE2)-induced maturation for
the last 24 hours. Finally, the CB-DC culture was electro-
porated with WT1-mRNA and their phenotype (cell surface
markers) and function (migration and antigen presentation)
were assessed.
Results: Using the two-step protocol a total cell expansion of
300-500 fold was achieved. Based on surface marker
expression, different DC subsets could be distinguished in
our CB-DC cultures. Since no differences in antigen presen-
tation capacity between the DC subsets were detected, the
whole CB-DC culture was used in all phenotypic and func-
tional assays. The maturation using CYTOMIX induced
upregulation of costimulatory molecules (CD80, CD83 and
CD86) and the chemokine receptor CCR7 on the CB-DCs.
These matured CB-DCs showed enhanced CCR7-dependent
migration towards CCL21 in a trans-well migration assay. The
presentation of WT1 peptides by the CB-DC culture, maturedusing CYTOMIX and electroporated with WT1 mRNA, was
conﬁrmed by the stimulation of T cells expressing a recom-
binant WT-1 peptide speciﬁc TCR. Furthermore, this same
CB-DC culture was able to induce expansion of the WT-1
speciﬁc T cells from their autologous pool of nave T cells in
cord blood. Conclusion: We have developed and tested an in
vitro system for culturing large amounts of DCs from the
CD34+ CB stem cells. Both the phenotypic and functional
data support the use of the whole CB-DC culture as vaccine.
We are currently translating our preclinical protocol to GMP
production of a clinical grade vaccine.183
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Autologous HPC transplants require the collection of sufﬁ-
cient HPCs to ensure engraftment. Inefﬁcient HPC harvests
lead to an over utilization of cytokines (GSCF, Plerixafor),
impose a limitation on storage space and lead to a waste of
resources, material and human. We report the use of an al-
gorithm based on a previously demonstrated positive linear
correlation between peripheral blood HPC dose and the
product HPC dose, to improve the efﬁciency of HPC collection
in patients undergoing autologous HPC harvests.
Methods: HPC collections on 62 consecutive patients were
analyzed. All patients received GCSF priming. Peripheral
blood CD34 (PHPC) counts were enumerated in 31 cases after
the adoption of the predictive algorithm (Cohort 2), and not
in the preceding 31 cases (Cohort 1). PHPC counts were
performed from day 4 of GCSF administration. Product CD34
count was expressed per kg of recipient weight. In Cohort 2
the predetermined algorithm was used to decide on the use
of Plerixafor and timing of collection. Based on peripheral
blood CD 34 counts (cells/mL) patients in Cohort 2 were
grouped into three categories (A:< 7, B:7-10,C:>10). Group A
received Plerixafor prior to collection. For group B the deci-
sion to use Plerixafor was deferred to the physician. Group C
did not receive Plerixafor prior to collection. Further dosing
of Plerixafor was determined by the product CD34 count. The
use of Plerixafor in the two cohorts was assessed retro-
spectively. The association between testing the PHPC count
and the use of Plerixafor was performed using the Chi Square
test. The Wilcoxon Rank Sum test was used to compare the
median number of collections between the two groups. The
proportional difference in patients receiving Plerixafor be-
tween the 2 cohorts was assessed using the Fisher Exact Test.
Results: In Cohort 1 (21 Myeloma and 10 Lymphoma) 80
collections were performed. In Cohort 2 (19 myeloma, 12
Lymphoma) 75 collections were performed. The target
collection was achieved in all patients. Forty three doses of
Plerixafor were administered in 14 patients in Cohort 1, and
21 doses in 6 patients in Cohort 2. The average daily charge
per collection with Plerixafor was $37728.9 and $11406,
without. There was a signiﬁcant association between the use
of a predictive PHPC count and following the algorithm, and
the use of Plerixafor (p ¼ 0.0011). The proportion of collec-
tions preceded by Plerixafor was higher when a PHPC count
was not performed (54% vs 28%, p¼ 0.0009). Proportionately,
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not performed (45% vs 19%, p ¼ 0.0279). There was no dif-
ference in the number of collections between Cohort 1
(Median¼2, R¼6) and Cohort 2 (Median¼2, R¼4, p¼0.99).
Conclusions: The use a predictive algorithm in deciding on
the timing of use of cytokines and HPC collection can lead to
potentially signiﬁcant savings on material resources and
cost, and improve the efﬁciency of collection.Figure. Mean serial killing of B-cell tumor (CD19pos NALM-6) by CD19-speciﬁc
CAR speciﬁc T cells (n¼3) using single cell serial imaging.184
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Adoptive T-cell immunotherapies are showing increasing
success for the treatment of malignancy. We have previously
demonstrated complete responses to Epstein-Barr Virus (EBV)
-speciﬁc T-cells (EBVSTs) directed against the EBV latent cycle
antigens, LMP1and LMP2 inover 50%of patientswithmultiply
relapsed or refractory EBV+ Hodgkin and non-Hodgkin lym-
phomas (HL and NHL)(1,2).
Unfortunately, themanufacturingproceduresused in this study
pose several impediments to the wider applicability of our
strategy. These include the use of live virus (EBV) and adeno-
viral (Ad) vectors and the difﬁculty of generating EBV-trans-
formed B-cell lines (EBV-LCL) for use as antigen-presenting
cells (APCs) from B-lymphoma patients in the rituxan-era.
To simplify manufacture and make our approach more
broadly applicable, we have replaced EBV antigens expressed
from Ad vectors with overlapping 15mer peptide libraries
(pepmixes) spanning LMP 1/2, as well as EBNA1 and BARF1,
and used pepmix-pulsed dendritic cells for the ﬁrst stimu-
lation followed by pepmix-pulsed, autologus activated T cells
(aATCs) and irradiated costimulatory cells (HLA-negative
K562 cells expressing CD80, CD86, CD83 and 41BB-ligand
[K562-CS] as transgenes) for further expansion.
To date, we have generated 15 EBVSTs from 11 patients (5 HL,
1 NK-T lymphoma, 3 lymphoproliferative diseases, 1 EBV+
diffuse large cell B lymphoma, 1 angioimmunoblastic T cell
lymphoma) enrolled on an IRB and FDA approved clinical
trial NCT01555892. All but one line satisﬁed the eligibility
criteria of the protocol. All EBVSTswere produced in less than
one month compared to 3-6 months with our previous
protocol (mostly due to the EBV-LCL generation). One patient
progressed before the line was ready, but we did not
encounter problems in patients pre-treated with rituxan (5/
11). At the time of cryopreservation EBVSTs were predomi-
nantly central memory (CD45RA-/62L+) (median 80%, range6-93%), while less than 22% (median 12%, range 4-22%) was
effector/effector memory T cells (CD45RA-/62L-). Using a
standard g-INF Elispot, we detected a response to at least 1
antigen in 5/11 patients and against 2 antigens in 2/11 pa-
tients. To date, we have treated 5 patients and while it is too
early to evaluate clinical efﬁcacy, we have detected increases
in the response to the viral antigens in vivo after the infusion.
We will continue to enroll, treat and perform the immuno-
logical follow up to correlate the immunological follow up
results with a clinical response.
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Adoptive cell therapy, based on the adoptive transfer of Tcells
genetically modiﬁed to enforce expression of a chimeric an-
tigen receptor (CAR) has shown considerable promise in
clinical trials, such as with CD19+ malignancies refractory to
conventional treatments. However, efﬁciently predicting
which patientmay beneﬁt from a given CAR design remains a
challenge and undermines the therapeutic potential of such
genetically modiﬁed T cells. Our approach to manufacturing
CD19-speciﬁc T cells is based on electro-transfer of DNA
plasmids from the Sleeping Beauty transposon/transposase
system and selective outgrowth of CAR+ T cells on irradiated
artiﬁcial antigen presenting cells (aAPC). The clinical-grade T
cells prepared for infusion comprise a heterogeneousmixture
and likely only a fraction of the genetically modiﬁed product
contributes to therapeutic efﬁcacy. Thus, we are developing
an approach whereby the therapeutic potential of individual
CAR+ Tcell canbe assessed. Tcells are capable of different anti-
tumor effector functions including cytotoxicity, cytokine
secretion, and homing to target tissues, and currently no
